LIVIVO - Search results -

Search results

Result 1 - 10 of total 67

Search options

Article ; Online: The fossil insect assemblage associated with the Toarcian (Lower Jurassic) oceanic anoxic event from Alderton Hill, Gloucestershire, UK.

Swaby, Emily J / Coe, Angela L / Ansorge, Jörg / Caswell, Bryony A / Hayward, Scott A L / Mander, Luke / Stevens, Liadan G / McArdle, Aimee

PloS one

2024 Volume 19, Issue 4, Page(s) e0299551

Abstract: Extreme global warming and environmental changes associated with the Toarcian (Lower Jurassic) Oceanic Anoxic Event (T-OAE, ~183 Mya) profoundly impacted marine organisms and terrestrial plants. Despite the exceptionally elevated abundances of fossil ... ...

Abstract	Extreme global warming and environmental changes associated with the Toarcian (Lower Jurassic) Oceanic Anoxic Event (T-OAE, ~183 Mya) profoundly impacted marine organisms and terrestrial plants. Despite the exceptionally elevated abundances of fossil insects from strata of this age, only assemblages from Germany and Luxembourg have been studied in detail. Here, we focus on the insect assemblage found in strata recording the T-OAE at Alderton Hill, Gloucestershire, UK, where <15% of specimens have previously been described. We located all known fossil insects (n = 370) from Alderton Hill, and used these to create the first comprehensive taxonomic and taphonomic analysis of the entire assemblage. We show that a diverse palaeoentomofaunal assemblage is preserved, comprising 12 orders, 21 families, 23 genera and 21 species. Fossil disarticulation is consistent with insect decay studies. The number of orders is comparable with present-day assemblages from similar latitudes (30°-40°N), including the Azores, and suggests that the palaeoentomofauna reflects a life assemblage. At Alderton, Hemiptera, Coleoptera and Orthoptera are the commonest (56.1%) orders. The high abundance of Hemiptera (22.1%) and Orthoptera (13.4%) indicates well-vegetated islands, while floral changes related to the T-OAE may be responsible for hemipteran diversification. Predatory insects are relatively abundant (~10% of the total assemblage) and we hypothesise that the co-occurrence of fish and insects within the T-OAE represents a jubilee-like event. The marginally higher proportion of sclerotised taxa compared to present-day insect assemblages possibly indicates adaptation to environmental conditions or taphonomic bias. The coeval palaeoentomofauna from Strawberry Bank, Somerset is less diverse (9 orders, 12 families, 6 genera, 3 species) and is taphonomically biased. The Alderton Hill palaeoentomofauna is interpreted to be the best-preserved and most representative insect assemblage from Toarcian strata in the UK. This study provides an essential first step towards understanding the likely influence of the T-OAE on insects.
MeSH term(s)	Humans ; Animals ; Fossils ; Oceans and Seas ; Hypoxia ; Insecta ; United Kingdom
Language	English
Publishing date	2024-04-17
Publishing country	United States
Document type	Journal Article
ZDB-ID	2267670-3
ISSN	1932-6203 ; 1932-6203
ISSN (online)	1932-6203
ISSN	1932-6203
DOI	10.1371/journal.pone.0299551
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Clinical Features of Psoriatic Arthritis: a Comprehensive Review of Unmet Clinical Needs.

McArdle, Angela / Pennington, Stephen / FitzGerald, Oliver

Clinical reviews in allergy & immunology

2017 Volume 55, Issue 3, Page(s) 271–294

Abstract: Psoriatic arthritis (PsA) is a form of inflammatory arthritis (IA) affecting approximately 0.25% of the population. It is a heterogeneous disorder associated with joint damage, disability, disfiguring skin disease and in severe cases, premature mortality. ...

Abstract	Psoriatic arthritis (PsA) is a form of inflammatory arthritis (IA) affecting approximately 0.25% of the population. It is a heterogeneous disorder associated with joint damage, disability, disfiguring skin disease and in severe cases, premature mortality. Inherently irreversible and frequently progressive, the process of joint damage begins at, or before, the clinical onset of disease. Early recognition and intervention is thus crucial to patient outcome. At disease onset, however, PsA often resembles other forms of arthritis-especially rheumatoid arthritis (RA). Despite the similarities between PsA and RA, their distinctive pathologies require different treatments. For example, drugs that are effective in RA may not be effective in PsA and can even cause adverse effects. Since there is no currently validated test for PsA, the diagnosis is often missed or delayed and this has functional consequences for the patient. In the context of PsA and RA, making an accurate diagnosis is not the only challenge faced by rheumatologists. Choosing an effective and safe medication to manage the disease is another significant challenge and currently approximately 40% achieve meaningful responses such as minimal disease activity status. For the patient, several months may be lost as a result of trial and error testing-meanwhile, irreversible joint damage may occur. Clearly, more effective clinical tests are urgently needed to improve personalised patient care in PsA. Specifically, there is need to develop minimally invasive tests predictive of diagnosis, response to treatment and radiographic progression. In this review, we examined the biomarker development process, highlighted the importance of qualifying unmet clinical needs and emphasised the challenges that impede biomarker studies. We have compiled a comprehensive list of potentially clinically relevant biomarkers in PsA and provided a summary of proteomic technologies that might usefully support additional biomarker research in PsA.
MeSH term(s)	Arthritis, Psoriatic/diagnosis ; Arthritis, Psoriatic/epidemiology ; Arthritis, Psoriatic/etiology ; Arthritis, Psoriatic/therapy ; Biomarkers ; Diagnostic Imaging ; Disease Management ; Disease Susceptibility ; Health Services Needs and Demand ; Humans ; Outcome Assessment (Health Care) ; Proteomics/methods ; Severity of Illness Index ; Symptom Assessment
Chemical Substances	Biomarkers
Language	English
Publishing date	2017-07-24
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1239045-8
ISSN	1559-0267 ; 1080-0549
ISSN (online)	1559-0267
ISSN	1080-0549
DOI	10.1007/s12016-017-8630-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1844: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Treatment of Multisystem Inflammatory Syndrome in Children: Understanding Differences in Results of Comparative Effectiveness Studies.

Melgar, Michael / Seaby, Eleanor G / McArdle, Andrew J / Young, Cameron C / Campbell, Angela P / Murray, Nancy L / Patel, Manish M / Levin, Michael / Randolph, Adrienne G / Son, Mary Beth F

ACR open rheumatology

2022 Volume 4, Issue 9, Page(s) 804–810

Abstract: Objective: Two cohort studies in patients with multisystem inflammatory syndrome in children (MIS-C) demonstrated contrasting results regarding the benefit of initial immunomodulatory treatment with intravenous immunoglobulin (IVIG) alone versus IVIG ... ...

Abstract	Objective: Two cohort studies in patients with multisystem inflammatory syndrome in children (MIS-C) demonstrated contrasting results regarding the benefit of initial immunomodulatory treatment with intravenous immunoglobulin (IVIG) alone versus IVIG and glucocorticoids. We sought to determine whether application of different MIS-C definitions and differing disease severity between cohorts underlay discrepant results. Methods: The Overcoming COVID-19 Public Health Surveillance Registry (OC-19) included patients meeting the US Centers for Disease Control and Prevention (CDC) MIS-C definition, whereas the Best Available Treatment Study (BATS) applied the World Health Organization (WHO) definition. We applied the WHO definition to the OC-19 cohort and the CDC definition to the BATS cohort and determined the proportion that did not meet the alternate definition. We compared illness severity indicators between cohorts. Results: Of 349 OC-19 patients, 9.5% did not meet the WHO definition. Of 350 BATS patients, 10.3% did not meet the CDC definition. Most organ system involvement was similar between the cohorts, but more OC-19 patients had WHO-defined cardiac involvement (87.1% vs 79.4%, P = 0.008). OC-19 patients were more often admitted to intensive care (61.0% vs 44.8%, P < 0.001) and more often received vasopressors or inotropes (39.5% vs 22.9%, P < 0.001) before immunomodulatory treatment. Conclusion: Greater illness severity and cardiovascular involvement in the OC-19 cohort compared with the BATS cohort, and not use of different MIS-C case definitions, may have contributed to differing study conclusions about optimal initial treatment for MIS-C. Disease severity should be considered in future MIS-C study designs and treatment recommendations to identify patients who would benefit from aggressive immunomodulatory treatment.
Language	English
Publishing date	2022-06-27
Publishing country	United States
Document type	Journal Article
ISSN	2578-5745
ISSN (online)	2578-5745
DOI	10.1002/acr2.11478
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Discovery Proteomics for COVID-19: Where We Are Now.

McArdle, Angela / Washington, Kirstin E / Chazarin Orgel, Blandine / Binek, Aleksandra / Manalo, Danica-Mae / Rivas, Alejandro / Ayres, Matthew / Pandey, Rakhi / Phebus, Connor / Raedschelders, Koen / Fert-Bober, Justyna / Van Eyk, Jennifer E

Journal of proteome research

2021 Volume 20, Issue 10, Page(s) 4627–4639

Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible coronavirus responsible for the pandemic coronavirus disease 2019 (COVID-19), which has had a devastating impact on society. Here, we summarize proteomic research that ...

Abstract	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible coronavirus responsible for the pandemic coronavirus disease 2019 (COVID-19), which has had a devastating impact on society. Here, we summarize proteomic research that has helped elucidate hallmark proteins associated with the disease with respect to both short- and long-term diagnosis and prognosis. Additionally, we review the highly variable humoral response associated with COVID-19 and the increased risk of autoimmunity.
MeSH term(s)	Autoimmunity ; COVID-19 ; Humans ; Pandemics ; Proteomics ; SARS-CoV-2
Language	English
Publishing date	2021-09-22
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	2078618-9
ISSN	1535-3907 ; 1535-3893
ISSN (online)	1535-3907
ISSN	1535-3893
DOI	10.1021/acs.jproteome.1c00475
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6189: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Discovery Proteomics for COVID-19: Where We Are Now

McArdle, Angela / Washington, Kirstin E. / Chazarin Orgel, Blandine / Binek, Aleksandra / Manalo, Danica-Mae / Rivas, Alejandro / Ayres, Matthew / Pandey, Rakhi / Phebus, Connor / Raedschelders, Koen / Fert-Bober, Justyna / Van Eyk, Jennifer E.

Journal of proteome research. 2021 Sept. 22, v. 20, no. 10

2021

Abstract	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible coronavirus responsible for the pandemic coronavirus disease 2019 (COVID-19), which has had a devastating impact on society. Here, we summarize proteomic research that has helped elucidate hallmark proteins associated with the disease with respect to both short- and long-term diagnosis and prognosis. Additionally, we review the highly variable humoral response associated with COVID-19 and the increased risk of autoimmunity.
Keywords	COVID-19 infection ; Severe acute respiratory syndrome coronavirus 2 ; autoimmunity ; humoral immunity ; pandemic ; prognosis ; proteome ; proteomics ; research ; risk
Language	English
Dates of publication	2021-0922
Size	p. 4627-4639.
Publishing place	American Chemical Society
Document type	Article
ZDB-ID	2078618-9
ISSN	1535-3907 ; 1535-3893
ISSN (online)	1535-3907
ISSN	1535-3893
DOI	10.1021/acs.jproteome.1c00475
Database	NAL-Catalogue (AGRICOLA)

In stock of ZB MED Cologne/Königswinter

Zs.A 6189: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The autoimmune signature of hyperinflammatory multisystem inflammatory syndrome in children.

Porritt, Rebecca A / Binek, Aleksandra / Paschold, Lisa / Rivas, Magali Noval / McArdle, Angela / Yonker, Lael M / Alter, Galit / Chandnani, Harsha K / Lopez, Merrick / Fasano, Alessio / Van Eyk, Jennifer E / Binder, Mascha / Arditi, Moshe

The Journal of clinical investigation

2021 Volume 131, Issue 20

Abstract: Multisystem inflammatory syndrome in children (MIS-C) manifests as a severe and uncontrolled inflammatory response with multiorgan involvement, occurring weeks after SARS-CoV-2 infection. Here, we utilized proteomics, RNA sequencing, autoantibody arrays, ...

Abstract	Multisystem inflammatory syndrome in children (MIS-C) manifests as a severe and uncontrolled inflammatory response with multiorgan involvement, occurring weeks after SARS-CoV-2 infection. Here, we utilized proteomics, RNA sequencing, autoantibody arrays, and B cell receptor (BCR) repertoire analysis to characterize MIS-C immunopathogenesis and identify factors contributing to severe manifestations and intensive care unit admission. Inflammation markers, humoral immune responses, neutrophil activation, and complement and coagulation pathways were highly enriched in MIS-C patient serum, with a more hyperinflammatory profile in severe than in mild MIS-C cases. We identified a strong autoimmune signature in MIS-C, with autoantibodies targeted to both ubiquitously expressed and tissue-specific antigens, suggesting autoantigen release and excessive antigenic drive may result from systemic tissue damage. We further identified a cluster of patients with enhanced neutrophil responses as well as high anti-Spike IgG and autoantibody titers. BCR sequencing of these patients identified a strong imprint of antigenic drive with substantial BCR sequence connectivity and usage of autoimmunity-associated immunoglobulin heavy chain variable region (IGHV) genes. This cluster was linked to a TRBV11-2 expanded T cell receptor (TCR) repertoire, consistent with previous studies indicating a superantigen-driven pathogenic process. Overall, we identify a combination of pathogenic pathways that culminate in MIS-C and may inform treatment.
MeSH term(s)	Adaptive Immunity ; Adolescent ; Autoimmunity ; Biomarkers/metabolism ; COVID-19/complications ; COVID-19/genetics ; COVID-19/immunology ; COVID-19/metabolism ; Case-Control Studies ; Child ; Child, Preschool ; Cohort Studies ; Cytokine Release Syndrome/immunology ; Female ; Humans ; Infant ; Inflammation/immunology ; Male ; Mucocutaneous Lymph Node Syndrome/genetics ; Mucocutaneous Lymph Node Syndrome/immunology ; Mucocutaneous Lymph Node Syndrome/metabolism ; Neutrophil Activation ; Proteomics ; RNA-Seq ; Receptors, Antigen, B-Cell/genetics ; Severity of Illness Index ; Systemic Inflammatory Response Syndrome/genetics ; Systemic Inflammatory Response Syndrome/immunology ; Systemic Inflammatory Response Syndrome/metabolism
Chemical Substances	Biomarkers ; Receptors, Antigen, B-Cell
Language	English
Publishing date	2021-08-26
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	3067-3
ISSN	1558-8238 ; 0021-9738
ISSN (online)	1558-8238
ISSN	0021-9738
DOI	10.1172/JCI151520
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.184: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Early acetaminophen-protein adducts predict hepatotoxicity following overdose (ATOM-5).

Chiew, Angela L / James, Laura P / Isbister, Geoffrey K / Pickering, John W / McArdle, Kylie / Chan, Betty S H / Buckley, Nicholas A

Journal of hepatology

2019 Volume 72, Issue 3, Page(s) 450–462

Abstract: Background & aims: Acetaminophen-protein adducts are specific biomarkers of toxic acetaminophen (paracetamol) metabolite exposure. In patients with hepatotoxicity (alanine aminotransferase [ALT] >1,000 U/L), an adduct concentration ≥1.0 nmol/ml is ... ...

Abstract	Background & aims: Acetaminophen-protein adducts are specific biomarkers of toxic acetaminophen (paracetamol) metabolite exposure. In patients with hepatotoxicity (alanine aminotransferase [ALT] >1,000 U/L), an adduct concentration ≥1.0 nmol/ml is sensitive and specific for identifying cases secondary to acetaminophen. Our aim was to characterise acetaminophen-protein adduct concentrations in patients following acetaminophen overdose and determine if they predict toxicity. Methods: We performed a multicentre prospective observational study, recruiting patients 14 years of age or older with acetaminophen overdose regardless of intent or formulation. Three serum samples were obtained within the first 24 h of presentation and analysed for acetaminophen-protein adducts. Acetaminophen-protein adduct concentrations were compared to ALT and other indicators of toxicity. Results: Of the 240 patients who participated, 204 (85%) presented following acute ingestions, with a median ingested dose of 20 g (IQR 10-40), and 228 (95%) were treated with intravenous acetylcysteine at a median time of 6 h (IQR 3.5-10.5) post-ingestion. Thirty-six (15%) patients developed hepatotoxicity, of whom 22 had an ALT ≤1,000 U/L at the time of initial acetaminophen-protein adduct measurement. Those who developed hepatotoxicity had a higher initial acetaminophen-protein adduct concentration compared to those who did not, 1.63 nmol/ml (IQR 0.76-2.02, n = 22) vs. 0.26 nmol/ml (IQR 0.15-0.41; n = 204; p <0.0001), respectively. The AUROC for hepatotoxicity was 0.98 (95% CI 0.96-1.00; n = 226; p <0.0001) with acetaminophen-protein adduct concentration and 0.89 (95% CI 0.82-0.96; n = 219; p <0.0001) with ALT. An acetaminophen-protein adduct concentration of 0.58 nmol/ml was 100% sensitive and 91% specific for identifying patients with an initial ALT ≤1,000 U/L who would develop hepatotoxicity. Adding acetaminophen-protein adduct concentrations to risk prediction models improved prediction of hepatotoxicity to a level similar to that obtained by more complex models. Conclusion: Acetaminophen-protein adduct concentration on presentation predicted which patients with acetaminophen overdose subsequently developed hepatotoxicity, regardless of time of ingestion. An adduct threshold of 0.58 nmol/L was required for optimal prediction. Lay summary: Acetaminophen poisoning is one of the most common causes of liver injury. This study examined a new biomarker of acetaminophen toxicity, which measures the amount of toxic metabolite exposure called acetaminophen-protein adduct. We found that those who developed liver injury had a higher initial level of acetaminophen-protein adducts than those who did not. Clinical trial registration: Australian Toxicology Monitoring (ATOM) Study-Australian Paracetamol Project: ACTRN12612001240831 (ANZCTR) Date of registration: 23/11/2012.
MeSH term(s)	Acetaminophen/toxicity ; Acetylcysteine/administration & dosage ; Administration, Intravenous ; Adolescent ; Adult ; Alanine Transaminase/blood ; Analgesics, Non-Narcotic/toxicity ; Australia/epidemiology ; Benzoquinones/blood ; Biomarkers/blood ; Chemical and Drug Induced Liver Injury/blood ; Chemical and Drug Induced Liver Injury/epidemiology ; Drug Overdose/blood ; Drug Overdose/drug therapy ; Drug Overdose/epidemiology ; Female ; Humans ; Imines/blood ; Liver/drug effects ; Liver/injuries ; Male ; Middle Aged ; Prospective Studies ; Treatment Outcome ; Young Adult
Chemical Substances	Analgesics, Non-Narcotic ; Benzoquinones ; Biomarkers ; Imines ; Acetaminophen (362O9ITL9D) ; Alanine Transaminase (EC 2.6.1.2) ; N-acetyl-4-benzoquinoneimine (G6S9BN13TI) ; Acetylcysteine (WYQ7N0BPYC)
Language	English
Publishing date	2019-11-22
Publishing country	Netherlands
Document type	Clinical Trial ; Journal Article ; Multicenter Study ; Observational Study ; Research Support, Non-U.S. Gov't
ZDB-ID	605953-3
ISSN	1600-0641 ; 0168-8278
ISSN (online)	1600-0641
ISSN	0168-8278
DOI	10.1016/j.jhep.2019.10.030
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2027: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Regional and Facility Differences in Interventions for Mastitis by Australian Physiotherapists.

Diepeveen, Lara Clare / Fraser, Elise / Croft, Anna Jane Elizabeth / Jacques, Angela / McArdle, Adelle M / Briffa, Kathy / McKenna, Leanda

Journal of human lactation : official journal of International Lactation Consultant Association

2018 Volume 35, Issue 4, Page(s) 695–705

Abstract: Background: Little information has been documented regarding interventions for mastitis by Australian physiotherapists. It is currently not known if physiotherapy interventions vary across Australian regions and types of healthcare facilities.: ... ...

Abstract	Background: Little information has been documented regarding interventions for mastitis by Australian physiotherapists. It is currently not known if physiotherapy interventions vary across Australian regions and types of healthcare facilities. Research aims: (1) To identify the interventions used by Australian physiotherapists treating mothers with mastitis and (2) to determine the variability in interventions used across regions and facilities. Methods: A retrospective observational design was used. A sample of case records of mothers with mastitis was identified ( Results: The physiotherapy interventions received by mothers included therapeutic ultrasound (n=175; 91.1%), education and advice ( Conclusions: Regional and facility differences exist in physiotherapy interventions for mastitis in Australia. Healthcare professionals who refer to physiotherapists for mastitis should be aware that interventions received may differ across regions and facility types.
MeSH term(s)	Attitude of Health Personnel ; Australia ; Breast Feeding ; Female ; Humans ; Infant, Newborn ; Mastitis/therapy ; Physical Therapists ; Physical Therapy Modalities ; Pregnancy ; Retrospective Studies
Language	English
Publishing date	2018-11-27
Publishing country	United States
Document type	Journal Article ; Multicenter Study ; Observational Study
ZDB-ID	1138470-0
ISSN	1552-5732 ; 0890-3344
ISSN (online)	1552-5732
ISSN	0890-3344
DOI	10.1177/0890334418812041
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3580: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Proteomics in Chronic Arthritis-Will We Finally Have Useful Biomarkers?

Kessel, Christoph / McArdle, Angela / Verweyen, Emely / Weinhage, Toni / Wittkowski, Helmut / Pennington, Stephen R / Foell, Dirk

Current rheumatology reports

2018 Volume 20, Issue 9, Page(s) 53

Abstract: Purpose of review: Current technical advances enable the assessment of the complex changes in body fluid proteomes and thus allow for the discovery of biomarker signatures rather than just following differences of a single marker. In this review, we aim ...

Abstract	Purpose of review: Current technical advances enable the assessment of the complex changes in body fluid proteomes and thus allow for the discovery of biomarker signatures rather than just following differences of a single marker. In this review, we aim to summarize current approaches to discover and evaluate multi-biomarker panels for improved monitoring of chronic arthritis disease activity. Recent findings: Mass spectrometry and affinity proteomic methodologies have been used to identify biomarker panels in synovial fluid, serum, plasma, or urine of pediatric and adult chronic arthritis patients. Notably, despite the numerous efforts to develop new and better biomarker panels, very few have undergone extensive analytical and clinical validation and been adopted into routine use for patient benefit. There remains a significant gap between discovery of chronic arthritis biomarker signatures and their validation for clinical use.
MeSH term(s)	Arthritis/diagnosis ; Biomarkers/analysis ; Chronic Disease ; Humans ; Mass Spectrometry/methods ; Proteomics/methods ; Reproducibility of Results
Chemical Substances	Biomarkers
Language	English
Publishing date	2018-07-14
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2057357-1
ISSN	1534-6307 ; 1523-3774
ISSN (online)	1534-6307
ISSN	1523-3774
DOI	10.1007/s11926-018-0762-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5531: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Efficacy and toxicity of primary re-irradiation for malignant spinal cord compression based on radiobiological modelling: a phase II clinical trial.

Wallace, Neil D / Dunne, Mary T / McArdle, Orla / Small, Cormac / Parker, Imelda / Shannon, Aoife M / Clayton-Lea, Angela / Parker, Michael / Collins, Conor D / Armstrong, John G / Gillham, Charles / Coffey, Jerome / Fitzpatrick, David / Salib, Osama / Moriarty, Michael / Stevenson, Michael R / Alvarez-Iglesias, Alberto / McCague, Michael / Thirion, Pierre G

British journal of cancer

2022 Volume 128, Issue 4, Page(s) 576–585

Abstract: Background: The efficacy and safety of primary re-irradiation for MSCC are not known. Our aim was to establish the efficacy and safety of biologically effective dose-based re-irradiation.: Methods: Patients presenting with MSCC at a previously ... ...

Abstract	Background: The efficacy and safety of primary re-irradiation for MSCC are not known. Our aim was to establish the efficacy and safety of biologically effective dose-based re-irradiation. Methods: Patients presenting with MSCC at a previously irradiated spine segment, and not proceeding with surgical decompression, were eligible. A 3 Gray per fraction experimental schedule (minimum 18 Gy/6 fractions, maximum 30 Gy/10 fractions) was used, delivering a maximum cumulative spinal dose of 100 Gy Results: Twenty-two patients were enroled, of whom eleven were evaluable for the primary outcome. Nine of eleven (81.8%) had stable or improved Tomita scores at 5 weeks. One of eight (12.5%) evaluable for late toxicity developed RIM. Conclusions: Re-irradiation is an efficacious treatment for MSCC. There is a risk of RIM with a cumulative dose of 120 Gy Clinical trial registration: Cancer Trials Ireland (ICORG 07-11); NCT00974168.
MeSH term(s)	Humans ; Spinal Cord Compression/radiotherapy ; Re-Irradiation ; Dose Fractionation, Radiation ; Spinal Cord Neoplasms/radiotherapy ; Treatment Outcome ; Radiation Injuries ; Radiotherapy Dosage
Language	English
Publishing date	2022-12-08
Publishing country	England
Document type	Clinical Trial, Phase II ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	80075-2
ISSN	1532-1827 ; 0007-0920
ISSN (online)	1532-1827
ISSN	0007-0920
DOI	10.1038/s41416-022-02078-w
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.142: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito